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Introduction
Although thyroid cancers represent approximately 1% of all 
new cancer diagnoses in the United States each year, it is the 
most common endocrine related cancer (1). The American 
Cancer Society estimated that approximately 44,670 new 
cases of thyroid cancer would be diagnosed in 2010. The 
overall incidence has risen from 1.3/100,000 for women 
and 4.6/100,000 for men in the year 1935 to 16.3/100,000 
for women and 5.6/100,000 for men in 2008 (2). 
The age & gender adjusted incidence has increased faster 
than that of any other malignancy in the recent years, with 
the majority of this increase belonging to small papillary 
thyroid carcinoma (PTC) (3).
Epidemiology
Thyroid cancers are divided into PTCs (80%), follicular 
thyroid carcinomas (FTCs) (10%), medullary thyroid 
carcinomas (5-10%) and anaplastic thyroid carcinomas 
(1-2%). Primary lymphomas and sarcomas are rare (1). 
PTC and FTC make up the well-differentiated thyroid 
carcinomas. The prognosis of the differentiated thyroid 
carcinomas (DTC) is generally excellent. Ten-year relative 
survival rates in a large cohort of United States patients 
with papillary and follicular cancer were, respectively, 93% 
and 85% (4). In one cohort study, 40 years recurrence 
rates were about 35%, two thirds of which occurred within 
the first decade after initial therapy. Thirty years cancer 
mortality rates were about 12% with local recurrence and 
43% with distant recurrence (5).
DTC
PTC is the most common type of differentiated thyroid 
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carcinoma. It is well known as a lymphotropic type of cancer 
and thus has high tendency to metastasize to regional lymph 
nodes (LNs) (6). Clinically evident nodal disease is present 
in approximately 5 to 10 percent of patients with PTC and 
a preoperative neck ultrasound can detect LN disease in 
up to 30 percent of patients (7-10). In contrast, less than 
five percent of patients with FTC develop nodal metastatic 
disease; the hematogenous rather than the lymphatic route 
is the primary pathway for metastasis (11). The prognosis of 
FTC is related to the age on presentation and the degree of 
capsular with or without vascular invasion. The diagnosis of 
FTC cannot always be made at the time of initial surgery. 
Prophylactic central neck dissection (pCND) during the 
first operation is of no value in FTC because the diagnosis 
of cancer is not established at that moment and also it tends 
not to spread via the lymphatic route.
Central neck dissection (CND) for PTC at the 
time of total thyroidectomy (TT)
The availability of non-invasive ultrasound and fine needle 
aspiration has led to detection of PTC in early stage. 
Higher incidence of small thyroid nodule with unknown 
cervical LNs status has posed a new management challenge 
to clinicians. Despite the excellent prognosis, many patients 
with PTC will develop nodal metastases in the central neck 
(level VI) or lateral neck (levels II, III, and IV) at the time 
of presentation or during the course of follow-up. 
The guideline from the National Comprehensive 
Cancer Network recommends CND only in the presence 
of clinically nodal disease. Similarly, the current standard 
of care for thyroid cancer based on the consensus guideline 
from American Thyroid Association (ATA), includes 
TT and a “therapeutic” LN dissection for patients with 
clinical evidence of nodal disease or a “prophylactic” 
CND in patients with a tumor more than 4 cm (T3 or 
T4 tumor) even in the absence of clinical evidence of 
nodal involvement (3). Most endocrine surgeons agree 
that compartment-based nodal dissection is appropriate 
for enlarged LNs that are identified on preoperative or 
during intraoperative inspection and palpation. However, 
substantial controversy still exists regarding the role of 
“prophylactic” neck dissection for patients with PTC. 
The neck dissection is defined by ATA as compartment 
oriented removal of all the lymphatic tissue with the 
fibroadipose tissue en bloc within the neck while preserving 
critical structures. A pCND is defined as resection of level 
VI LNs that appear normal in preoperative imaging and 
intra-operative assessment. Anatomical neck level VI or 
central compartment of the neck refers to the LNs that 
located between the carotid arteries from the innominate 
artery to the hyoid bone, includes the pretracheal, 
prelaryngeal and parartracheal LNs (3).
In general, cervical nodal metastasis tends to spread in a 
stepwise fashion from the thyroid to the ipsi-lateral central 
(level VI), then to the lateral compartment (level II to V) 
and/or contra-lateral central compartment. Therefore, the 
central compartment is considered to be the first echelon of 
nodal metastasis in thyroid cancer. Theoretically, removal 
of central LNs may alter the prognosis of thyroid cancer 
especially in PTC. Many endocrine surgeons have advocated 
pCND in their patient without clinical or radiographic 
evidence of LN involvement at the time of TT (12). 
The actual role of pCND in thyroid cancer remains a major 
topic of debate. This article aimed to review the arguments 
for and against pCND in PTC.
Arguments for pCND in clinically nodal negative 
(cN0) PTC
(I) Metastatic disease to central compartment LNs is 
frequently identified in patients with PTC. Nodal disease 
is an important issue in managing patients with thyroid 
cancer. According to ATA, LN metastasis is present in up 
to 20-50% of the patients undergoing an elective node 
dissection for PTC and up to 90 percent of patients will 
have microscopic metastatic disease (13,14). Sergio Zuniga 
et al. demonstrated that in 136 patients who underwent 
pCND, 82.3% (112 patients) had metastatic LNs (15). 
Similar conclusion was drawn by Roh et al. in which 
51 (62.2%) out of 82 patients with neck dissection had LN 
metastases in the central neck compartment (16). Therefore, 
there were significant numbers of patients undergoing TT 
for cN0 PTC without pCND are likely to have occult nodal 
disease left behind in the neck.
(II) Some studies have raised the possibility that failure to 
remove tumour bearing cervical LN could be detrimental in 
patient with PTC. Cervical LN metastasis is associated with 
higher risk of disease recurrence and cancer mortality. This 
is supported by the following studies: 
(i) In a retrospective review by Wada et al., among 
134 pat ients  with papi l lary  thyroid cancer 
undergoing TT with neck dissection, 17 patients 
(12.7%) developed local recurrence in cervical 
LNs. Recurrence rate was significantly higher for 
patients undergoing a therapeutic neck dissection 
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for suspicious lymphadenopathy (n=42) when 
compared to patients undergoing an elective neck 
dissection (END) with no lymphadenopathy [23.8% 
(10 patients) versus 7.6% (7 patients)]. Microscopic 
disease was identified in 62 of 92 patients (67.4%) 
undergoing an END. Of the 62 patients with 
microscopic nodal disease, the local recurrence rate 
was 11.3%. Of the 30 patients with histologically 
negative nodes, there were no local recurrences. Of 
the 104 patients with histologically positive nodes, 
the local recurrence rate was 16.3%. Thus, he 
concluded that lymphadenopathy and microscopic 
nodal status were significantly associated with 
recurrences and disease free survival rates (17).
(ii) In a Cox regression model, studied of 1,355 patients 
with 30 years of follow-up, the likelihood of cancer 
death was increased by regional lymph-node 
metastases in patients without distant metastases (18).
(iii) Additional data from Surveillance Epidemiology and 
End Results database comprising 19,918 patients 
showed that for those with LN metastasis, the 
14-year survival rate was 79% and was 82% in 
non-metastatic patients (P<0.05) (19). 
Based on the above findings, there are potential benefits 
of lower recurrence in those who underwent pCND. Table 1 
summarizes the local regional recurrence rates between 
those underwent TT with prophylactic neck dissection and 
those who underwent TT alone. 
In contrast, a recent meta-analysis by Zetoune et al., 
comprising five retrospective comparative studies (n=1,264), 
found that there was an “insignificant” trend toward lower 
overall recurrence rate in the group who underwent either 
unilateral or bilateral pCND when compared to those who 
had TT only (2.02% versus 3.92%, odds ratio =1.05, 95% 
CI, 0.48-2.31) (28). Furthermore, people may argue that the 
subclinical LN metastasis could be ablated by radioactive 
iodine post operation. But, it is worth noting that not all 
tumours will respond to RAI ablation. 
(III) Ultrasound neck and aspiration cytology are 
currently the preferred investigation tools for evaluation of 
the thyroid and cervical LN. However, detection of central 
compartment LN metastasis using ultrasound remains 
diﬃcult even in expert hand because the abnormal central 
LNs are often small in size and frequently located deep 
inside the neck or just posterior to the sternum (29-31), 
where the overlying thyroid gland often hinders adequate 
visualization (32). 
Kim et al. found that preoperative ultrasound has an 
accuracy of 77% only in detection of LN metastasis. 
Despite the fact that ultrasound has high specificity of 
Table 1 A comparison of local regional recurrence rates between those underwent total thyroidectomy with prophylactic neck dissection 
(TT + CND) and those underwent total thyroidectomy (TT) alone
Author Follow up period
No of patients Local regional recurrence rate (%)
P-value
TT + CND TT TT + CND TT
So et al.  
2012 (20)
44.7 months (CND);  
45.4 months (TT)
119 113 1.7 3.5 Not significant
Lang et al.  
2011 (21)
Median: 26 months 82 103 3.7 2.9 1.0
Moo et al.  
2012 (22) 
3.1 years 45 36 4.4 16.7 0.13
Costa et al.  
2009 (23)
Mean: 47 months (CND);  
64 months (TT)
126 118 6.3 7.7 0.83
Gemsenjager et al.  
2003 (24)
Median: 6.5 years 29 88 3 2 Not reported
Wada et al.  
2003 (25)
Mean: 52 months 235 155 0.43 0.65 Not significant
Syawak et al.  
2006 (26) 
Median: 24.5 months (CND);  
70 months (TT) 
56 391 3.6 5.6 Not reported
Roh et al. 2007 (16) Mean: 52 months 82 (PCND: 40) 73 0 2.6 0.37
Bardet et al.  
2008 (27)
15 months 181 (with lateral 
neck dissection)
161 2.8 3.7 Not reported
Abbreviations: TT, total thyroidectomy; CND, central neck dissection.
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92% and positive predictive value of 81%, the sensitivity is 
only 51% and the negative predictive value is 76% (33,34). 
Other sophisticated imaging modalities such as computer 
tomography and magnetic resonance imaging have not 
shown any additional advantage, they are more beneficial in 
patients with extensive nodal involvement. Because of the 
lymphadenopathy cannot be reliably assessed by imaging 
studies, pCND has been advocated. Prophylactic CND 
allows histology examination of LNs and more accurate 
pathological staging.
Wang et al. reviewed 49 patients (48%) who were 
cN0 PTC and found that pCND resulted in detection of 
unsuspected metastasis lymphadenopathy in 20 (41%) of 
patients and changed RAI recommendation in 14 (33%) 
of patients (35). Similarly, in a study performed in our 
hospital, of 82 patients underwent pCND, 17.1% were 
upstaged from stage I/II to stage III due to detection of 
nodal metastasis after surgery (21). 
(IV) A detectable post-operation Thyroglobulin (Tg) 
level is a surrogate marker of persistent or recurrent thyroid 
cancer after TT and RAI ablation. Prophylactic CND 
results in a higher rate of stimulated athyroglobulinemia 
after surgery. Hence, it could facilitate follow up and cancer 
surveillance of the neck. The relation between pCND and 
Tg was illustrated by the following studies: 
(i) Sywak et al. examined 447 patients with clinically 
node-negative PTC. 56 patients underwent TT 
plus pCND. There was a significantly lower level of 
stimulated Tg at six months after RAI ablation (mean: 
0.4 versus 9.3 mg/L, P<0.02) and higher proportion of 
athyroglobulinemia (72% versus 43%; P<0.001) (26). 
(ii) In a study compared serum Tg level in 113 patients 
underwent TT alone with 119 patients underwent 
TT in conjunction with pCND bilaterally: the post-
operative Tg was significantly less in pCND group 
(1.07 vs. 2.24 ng/mL respectively; P=0.022). However, 
the two groups became similar after low dose 
radioactive iodine treatment (0.44 vs. 0.69 ng/mL 
respectively; P=0.341). There was also no significant 
difference in three years local-regional control 
rate in both the studied groups (98.35% vs. 96.5%; 
P=0.368). Thus, he concluded that pCND lower the 
serum Tg level but is not helpful in decreasing short 
term recurrence in patient with cN0 PTC (20).
(iii) Lang et al .  analysed 185 patients with PTC 
retrospectively. In this study, 82 (44.3%) patients 
underwent unilateral TT with pCND and found 
that this group of patient has lower median pre-
ablative-stimulated Tg level (<0.5 versus 6.7 μg/L, 
P<0.001) and achieved a higher rate of pre-ablative 
athyroglobulinemia (51.2% versus 22.3%, P=0.024) 
than those who underwent a TT only. However, 
these diﬀerences were not observed six months after 
ablation (31). The most likely explanation for this 
difference was that the residual microscopic disease 
was ablated by RAI ablation subsequently. Thus, the 
group without pCND achieved similar stimulated 
Tg levels and similar rate of athyroglobulinemia 
six months after ablation (36). 
Unlike the above studies, no difference was found by 
Raffaelli M et al. concerning mean post-operative basal 
and stimulated Tg after a prospective evaluation of total 
186 patients with cN0 underwent TT with or without; 
ipsi- or bilateral CND (37). Similarly, Hughes et al. also 
found that there was no diﬀerence in post-ablation median- 
stimulated Tg level or rate of athyroglobulinemia between 
patients underwent TT with or without bilateral pCND (38).
(V) Thyroid cancer patients without pCND are at 
higher risk of neck recurrence which may require second 
operation. Re-operation is associated with a higher 
morbidity than pCND when done at the time of initial 
TT. Complications such as iatrogenic injuries of the nerve 
and parathyroid gland would be higher in re-operative 
central lymph node dissection (CLND) because of the 
scarring in the operative field and distorted anatomy 
in the central neck after TT. For example, Segal et al. 
who had reviewed 503 patients retrospectively found that 
reoperation had a significantly higher complication rate of 
permanent recurrent nerve injury (25% versus 5.8%) and 
hypoparathyroidism (8.3% versus 5.0%) compared with 
primary operation (39). Other studies also revealed similar 
outcomes (40-43). It is reasonable to dissect LNs in the 
central compartment routinely, because subsequent surgery 
for node metastases in this area poses more difficulties. On 
the other hand, Shen et al. argued that neck reoperation 
could also be performed as safely as first operation by 
an “experienced” surgeon. In his study, the initial and 
re-operative CLND had similar complication and 
recurrence rates (44).
Arguments against pCND in cN0 PTC
(I) The most frequently quoted data arguing against the 
need for routine pCND is increased risk of transient 
hypoparathyroidism. Risk of transient hypocalcemia has 
been consistently shown in many studies (Table 2). 
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(i) Moo et al. found that the rates of temporary 
hypocalcemia were higher in CND group compared 
to no neck dissection group (31% versus 5 %; P=0.01). 
Interestingly, the rate of permanent hypocalcemia 
were the same (5% versus 0%; P=0.41) (22). 
(ii) A meta-analysis found that patients with pCND 
were almost 2.5 times more likely to have temporary 
hypocalcemia than those who underwent TT alone 
(26.0% vs. 10.8%; OR=2.56; 95% CI: 1.75-2.57) (48).
(iii) So et al. reviewed 232 patients who underwent 
surgery for clinically node negative papillary thyroid 
micro-carcinoma from 1999 to 2006, reported 
that the frequency of permanent hypocalcemia was 
approximately 3 times greater in TT with pCND 
(5.9%) than TT only (1.8%) although this finding 
did not reach statistical significance (20). 
(iv) A recent systematic review of five retrospective 
studies, evaluated the morbidity of pCND and 
found that there was one extra case of transient 
hypocalcaemia for every eight pCNDs performed (49). 
However, there was no increased risk of permanent 
hypocalcaemia and recurrent laryngeal nerve injury. 
The higher rate of temporary hypoparathyroidism 
could be explained by the higher chance of 
unintentional removal or devascularisation of 
parathyroid glands during dissection.
Prophylactic CND also contributes to the higher rate 
of temporary recurrent laryngeal nerve injury in a study 
by Shindo et al. (45) (Table 3). Palestini et al. reported 
four times higher rate of transient recurrent laryngeal 
nerve injury in patients underwent TT plus bilateral neck 
dissection (1.4% versus 5.4%, P=0.059), although it was not 
statistically significant (46). To date, no studies have shown 
an increase risk of “permanent” recurrent laryngeal nerve 
injury in patient underwent pCND. A good example was a 
study by Giordano et al. as shown in Table 3 (47).
In general, surgical morbidity correlates with the extent 
of surgical dissection and the operation skill of surgeons. 
Since the risks of transient complications are high, especially 
when performed by low volume surgeons (fewer than 
50 cases/year), a selective approach should be considered 
by determine which patients are likely required pCND 
pre-operatively and the experience of the surgeon (51). 
Several studies described the risk factors that associated 
with LN metastasis  in PTC but the results  were 
inconsistent (46,52,53). In a study by So et al., the male 
gender, tumour multi-focality and extra-thyroidal extension 
were independently predictive of subclinical central LN 
Table 2 A comparison of the rate of hypoparathyroidism (hypocalcemia) between total thyroidectomy (TT) alone and total thyroidectomy 







TT + CND TT alone TT + CND TT alone TT + CND TT alone
Moo et al.  
2010 (22)
45 35 31 5 0.001 0.0 5.0 0.41
So et al.  
2012 (20)
119 113 41.2 33.6 0.235 5.9 1.8 0.105
Lang et al.  
2011 (21)
82 103 18.3 8.7 0.017 2.4 1.0 1.000
Shindo et al.  
2010 (45)
122 134 13.1 25.4 0.02 0.8 0.7 0.99
Palestini et al.  
2008 (46)
93 148 26.9 12.8 0.003 0.0 2.7 0.2
Roh et al.  
2007 (16)
82 73 30.5 9.6 0.001 4.9 0.0 0.056
Sywak et al.  
2006 (26)
56 391 18 8 0.02 1.8 0.5 0.27




394 36.1 (unilateral), 
51.9 (bilateral)




6.3 0.818 (unilateral), 
<0.001 (bilateral)
Abbreviations: TT, total thyroidectomy; CND, central neck dissection.
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metastasis. It was recommended that patient with these 
features should be considered for pCND (52). However, 
realistically only male sex is known preoperatively. Some 
researchers also believed that large tumour size, patients 
who have decreased capacity for RAI and those with BRAF 
mutation should be undergoing pCND at the time of 
TT (36). Alternatively, suspected LN that found intra-
operatively may be confirmed by frozen section examination 
before proceeding to neck dissection.
(II) LN involvement in papillary thyroid cancer can 
be macroscopic (identified on preoperative imaging or 
intraoperative inspection) or microscopic (identified on 
pathologic review only). Macroscopic LN involvement is 
associated with a significant higher rate of local recurrence 
(10-42%) (54,55). It is unknown what the natural history is, 
in PTC with only microscopic LN involvement/subclinical 
nodal metastasis.
Studies have shown that only subclinical metastatic LNs 
would be identified at the time of pCND for small PTC (56). 
Wada et al. studied microscopic regional LN status in 
92 patients with PTC underwent pCND and found that 
only few nodes (mean 2.7 nodes/17.8%) were involved 
pathologically when there was no lymphadenopathy 
clinically (31). Besides, Vergez et al. also found in their 
study that most of these pathologically involved LN 
were subclinical and less that 5 mm in size (66%) (57). 
With the advances of radio-active iodine ablation, these 
micrometastasis wouldn’t ultimately result in poorer 
prognosis. Additionally, it is doubtful that this subclinical 
occult LN metastasis would eventually develop into 
clinically significant recurrences in the future. 
(i) In another data presented by Wada et al. on 259 
patients with papillary microcarcinoma of thyroid, 
of mean 53 months follow up, LN metastasis was 
frequent in the pCND group (60.9%) for central 
compartment and 39.5% for ipsilateral lateral 
compartment. While, only 0.43% patient underwent 
prophylactic neck dissection developed recurrence 
despite high microscopic LN involvement (25). The 
nodal recurrence did not differ between the pCND 
group and the no-dissection group (0.43% vs. 
0.65%).
(ii) Gemsenjäger et al. reported a similar finding in their 
study of 159 patients with PTC and concluded that 
the rate of occult nodal disease was relatively low and 
it did not frequently progress to clinical recurrent 
disease (24). 
In summary, for patients harbouring central neck 
compartment “micrometastasis”, pCND dissection may only 
provide a limited benefit in terms of reducing recurrence. 
Routine CND targeted at subclinical LN metastasis has 
little prognostic benefit. Unnecessary CND will prolong 
Table 3 Recurrent laryngeal nerve or vocal cord injuries in the total thyroidectomy with and without central neck dissection
Author
No of patients Transient vocal cord palsy (%)
P-value
Permanent vocal cord palsy (%)
P-value
TT + CND TT alone TT + CND TT alone TT + CND TT alone
So et al.  
2012 (20)
119 113 3.4 3.5 0.941 0.8 1.8 0.531




394 3.9 (unilateral),  
5.5 (bilateral)
3.6 0.404 0.5 (unilateral), 
2.3 (bilateral)
1.0 0.099
Lang et al.  
2011 (21)
82 103 1.8 0.0 0.324 0.6 0.5 0.443
Shindo et al.  
2010 (45)
122 134 0.0 4.5 0.03 0.0 0.0 –
Sadowski et al. 
2009 (50)
169 130 8.9 4.6 0.18 2.4 3.1 1.0
Palestini et al. 
2008 (46)
93 148 5.4 1.4 0.059 0.0 1.4 0.344
Roh et al.  
2007 (16)
82 73 7.3 4.1 0.394 3.6 2.7 0.747
Sywak et al.  
2006 (26)
56 391 1.8 1.0 0.62 0.0 1.0 0.45
Abbreviations: TT, total thyroidectomy; CND, central neck dissection.
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operation time and increase surgical complications.
(III) There is also little evidence to show that pCND 
improves cancer-specific survivals in “cN0 PTC”. 
(i) A survical benefit for pCND in DTC was suggested 
in a study carried out by Tisell et al. (58). They 
evaluated 175 patients who underwent TT with 
CND and compared with contemporaneous controls 
from two other studies conducted on patients in 
Norway and Finland (59,60). They showed that 
patients who underwent TT with pCND had 
a higher survival rate (1.6% versus 8.4-11.1%). 
However, this study was limited by lack of statistical 
comparison between the studies.
(ii) In the retrospective review of 244 patients by 
Costa et al., found that central neck metastasis was 
predictive of disease recurrent but not influencing 
the prognosis. The overall recurrence rate in his 
paper was 6.35 % (8/126; mean follow-up of 47 
months) in TT plus pCND group and 7.7% (9/118; 
mean follow-up of 64 months) in TT alone group 
(P=0.83). Of those underwent pCND, 47% were 
diagnosed pN1a but there was no difference in 
survival rate statistically (23).
(iii) Additional finding came from a cohort analysis of 
266 patients with 6.3 years mean follow up and the 
study reported that the 5-year disease-free survival 
was comparable; 88.2% in the CND group versus 
85.6% in the group that did not undergo CND 
(P=0.72) (15). Absented of survival benefit with more 
extensive surgery and longer operation time have 
limited the routine application of pCND (24).
(IV) The number of positive cervical LNs could affect 
the disease stage. Prophylactic CND provides more 
accurate pathological staging and hence, greater incidence 
of N1a is found. In a study conducted by our hospital 
demonstrated that 17.1% of 82 patients were upstage from 
stage I/II to III after pCND (21). Basically, the pathological 
staging of the tumour for patients aged more than 45 years 
old are changed to higher stage III (AJCC/UICC TNM 
staging system) even without any extra-thyroidal extension 
or other poor prognostic factors (61,62). The outcome of 
stage migration will be reflected in the overall cancer-specific 
survival rate. Confusion may occur as they would be classified 
as stage III with lower 10-year survival (85-90%) while those 
patients younger than 45 would still remain as stage I with 
10-year survival rates of more than 95% (31,61-64). 
(V) Because of upstaging, more patients would receive 
RAI ablation and higher doses of RAI, which might not 
be necessary in certain patients. In a retrospective study, 
Hughes et al. had observed that patients in the TT plus 
pCND group received significantly higher dose of RAI than 
those in the TT group (150 vs. 30 mCi, P=0.01). Despite a 
higher dose of RAI, there was no difference in central neck 
recurrence between TT plus pCND and TT alone group. 
The author concluded that pCND allows stratification of 
patient to receive higher doses of RAI but not affected the 
local recurrence rate (38). Table 4 revealed the published 
series of doses of I-131 used during RAI ablation. pCND 
increased LN positivity and has encouraged higher usage 
of RAI. This is foreseeable that increase of health care costs 
will be one of the major concerns in the future. 
Although the treatments with 131-I are generally 
safe and well-tolerated, patients would still be subjected 
to potential short- and long-term side-effect of RAI. 
RAI is contraindicated in patients who are pregnant or 
breastfeeding. Men who receive RAI treatment for thyroid 
cancer may have decreased sperm counts and temporary 
infertility for a period of roughly two years (65,66). 
Furthermore, Lee et al. found that nausea, vomiting, 
ageusia (loss of taste), salivary gland swelling, sialoadenitis 
associated xerostomia, dental caries, pulmonary fibrosis, 
naso-lacrimal outflow obstruction, and, more importantly, 
increased risk of second primary malignancies are associated 
with radioiodine therapy (67,68). I-131 is preferentially 
taken up by normal and malignant thyroid follicular cells, 
but it is also accumulated in the stomach, salivary glands, 
colon, and bladder; salivary glands and breast tissue contain 
sodium iodide transporters. The risk of salivary gland, 
Table 4 Mean doses of radioactive iodine ablative therapy
Author
No of patients Mean dose of I-131 per treatment P-value
TT + CND TT alone TT + CND TT alone
Moo et al. 2010 (22) 45 36 102.7 mCi 66.3 mCi 0.002
Hughes et al. 2010 (38) 78 65 150.0 mCi 30.0 mCi 0.01
Sywak et al. 2006 (26) 56 391 5.2 GBq 4.8 GBq 0.2
Abbreviations: TT, total thyroidectomy; CND, central neck dissection.
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breast, bladder and gastrointestinal cancers can theoretically 
increase in thyroid cancer patients treated with radioiodine. 
The risk is typically more prominent between two and ten 
years after therapy with a prevalence of about 0.5% (65,66).
Conclusions
The extent of dissection in the neck is a balance between 
the greater morbidity of a more extensive neck dissection 
and the possibility of leaving residual untreated metastatic 
LN. There is little good evidence (level II or better) to 
justify pCND in all cN0 PTC. Our review has summarized 
the conflicting recommendations in which the applicability 
to clinical practice remains questionable. Further studies in 
this controversial subject are much needed.
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